Key result
One-day PAH-SYMPACT symptom scores highly correlated with the seven-day weekly average and differentiated well between WHO functional classes II and III/IV pulmonary arterial hypertension.
Why the study?
Does a one-day symptom reporting version of the PAH-SYMPACT tool correlate with the seven-day weekly average and differentiate disease severity in patients with pulmonary arterial hypertension?
Observational
Does a one-day symptom reporting version of the PAH-SYMPACT tool correlate with the seven-day weekly average and differentiate disease severity in patients with pulmonary arterial hypertension?
A one-day version of the PAH-SYMPACT questionnaire is feasible, correlates well with the seven-day version, and is sensitive to disease severity, making it appropriate for routine clinical practice.
Answers are grounded in this paper and cite their sources.
May enable simpler daily PAH symptom tracking; leaves open prospective validation before routine use.
Patient-reported outcomes are important measures to include in pulmonary arterial hypertension clinical trials but are not widely utilized in clinical practice. Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire (PAH-SYMPACT) is the only pulmonary arterial hypertension-specific patient-reported outcomes instrument developed and validated in accordance with the US Food and Drug Administration guidance on patient-reported outcomes development. The PAH-SYMPACT tool measures pulmonary arterial hypertension-related symptoms and impact of pulmonary arterial hypertension on daily life. Symptoms are reported each day for seven consecutive days, and the impact of pulmonary arterial hypertension over one week is recalled and reported on day 7; however, daily symptom reporting may overburden patients and healthcare resources, limiting the practicality of PAH-SYMPACT outside of clinical trials. To determine the practicability of an abridged version of PAH-SYMPACT for which all reporting is completed on one day, symptom data from the SYMPHONY trial (NCT01841762; PAH-SYMPACT validation study) were retrospectively analyzed to assess whether symptoms reported on each day correlated with the weekly average and whether one-day symptom scores were sensitive to disease severity. Correlation coefficients comparing the weekly average and individual day symptom scores were mostly high or very high regardless of the day they were measured. Findings were similar when using either Spearman's rank correlation or weighted kappa method. One-day symptom scores differentiated well between World Health Organization functional classes II and III/IV pulmonary arterial hypertension and were sensitive to change in disease severity as measured by the Patient Global Assessment of Disease Severity. These data suggest that the one-day PAH-SYMPACT is feasible and appropriate for routine implementation in clinical practice.
No takes yet. Share an insight, caveat, or question.
Frantz et al. (2020) conducted an observational in Pulmonary arterial hypertension. One-day PAH-SYMPACT symptom reporting vs. Seven-day PAH-SYMPACT symptom reporting was evaluated on Correlation between one-day symptom scores and weekly average, and sensitivity to disease severity. One-day PAH-SYMPACT symptom scores highly correlated with the seven-day weekly average and differentiated well between WHO functional classes II and III/IV pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: